Search / 14 results found

  • Updated

EXTON, Pa., July 14, 2021 /PRNewswire/ -- As expected with the recent media maelstrom surrounding its June 7th approval, unaided and aided awareness of Biogen's Aduhelm, the first disease-modifying therapy (DMT) for the treatment of Alzheimer's disease, is almost ubiquitous among US neurologists. However, with the first patients not being dosed until mid-June, few neurologists report having personal experience prescribing the monthly infusion monoclonal antibody (mAb) to their patients.

  • Updated

PHILADELPHIA, June 29, 2021 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines by 50% or more without compromising the quality of clinical data generated or the scientific impact of Signant's in-house therapeutic area expertise on study outcomes.

The Food and Drug Administration on Monday approved the first new treatment for Alzheimer’s disease in about 20 years. Currently available Alzheimer’s drugs treat the disease’s symptoms. The newly-approved medicine, called Aduhelm, is the first to attack a substance that could be associated with the underlying causes of the disease — a toxic and sticky […]

There are a hundred things I could tell you about my late mother that are more important than the disease that caught her in its grip the last…